Amphastar pharmaceuticals reports financial results for the three months and full-year ended december 31, 2021

Reports net revenues of $120.9 million for the three months ended december 31, 2021 rancho cucamonga, ca / accesswire / march 10, 2022 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") today reported results for the three months and full-year ended december 31, 2021. fourth quarter highlights net revenues of $120.9 million for the fourth quarter gaap net income of $19.8 million, or $0.39 per share, for the fourth quarter adjusted non-gaap net income of $20.8 million, or $0.42 per share, for the fourth quarter full-year highlights net revenues of $437.8 million for the fiscal year gaap net income of $62.1 million, or $1.25 per share, for the fiscal year adjusted non-gaap net income of $68.0 million, or $1.37 per share, for the fiscal year dr. jack zhang, amphastar's president and chief executive officer commented: "last year was a turning point for amphastar - with financial strength driven by the continued growth of our higher-margin products.
AMPH Ratings Summary
AMPH Quant Ranking